DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vfend (Voriconazole) - Summary

 
 



VFEND SUMMARY

VFEND® I.V.
(voriconazole) for Injection

VFEND® Tablets
(voriconazole)

VFEND® (voriconazole) for Oral Suspension

VFEND® (voriconazole), a triazole antifungal agent, is available as a lyophilized powder for solution for intravenous infusion, film-coated tablets for oral administration, and as a powder for oral suspension.

VFEND is indicated for use in the treatment of the following fungal infections:

Invasive aspergillosis. In clinical trials, the majority of isolates recovered were Aspergillus fumigatus. There was a small number of cases of culture-proven disease due to species of Aspergillus other than A. fumigatus.

Esophageal candidiasis.

Serious fungal infections caused by Scedosporium apiospermum (asexual form of Pseudallescheria boydii) and Fusarium spp. including Fusarium solani, in patients intolerant of, or refractory to, other therapy.

Specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained prior to therapy to isolate and identify causative organism(s). Therapy may be instituted before the results of the cultures and other laboratory studies are known. However, once these results become available, antifungal therapy should be adjusted accordingly.


See all Vfend indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Vfend (Voriconazole)

Cancer patients benefit from isavuconazole, a new antifungal
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2014.09.09]
A newly developed antifungal, isavuconazole, is as effective as an existing drug, voriconazole, against invasive mold disease in cancer patients with less adverse effects, according to phase 3...

more news >>

Published Studies Related to Vfend (Voriconazole)

Voriconazole versus natamycin as primary treatment in fungal corneal ulcers. [2011.07]
BACKGROUND: To evaluate the efficacy of topical 1% voriconazole versus 5% natamycin in treatment of fungal corneal ulcers. DESIGN: A prospective, randomized pilot study in a tertiary care hospital. PARTICIPANTS: Thirty patients of microbiologically proven fungal keratitis divided randomly in two groups of 15 patients each... CONCLUSION: Topical 1% voriconazole was found to be safe and effective drug in primary management of fungal keratitis, its efficacy matching conventional natamycin. There was no added advantage of using topical 1% voriconazole over topical natamycin as primary treatment in fungal keratitis. (c) 2011 The Authors. Clinical and Experimental Ophthalmology (c) 2011 Royal Australian and New Zealand College of Ophthalmologists.

Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. [2011.01]
PURPOSE: To compare the efficacy and safety of voriconazole with itraconazole as prophylaxis in leukemia patients... CONCLUSIONS: Voriconazole is a good alternative for prophylaxis in patients with leukemia. Elevated baseline bilirubin levels were associated with a higher risk of side effects in patients receiving i.v. voriconazole or i.v. itraconazole. Monitoring of liver function and drug levels should be considered for some patients.

Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. [2010.12.09]
Invasive fungal infection (IFI) is a serious threat after allogeneic hematopoietic cell transplant (HCT)...

Long-term visual safety of voriconazole in adult patients with paracoccidioidomycosis. [2010.12]
BACKGROUND: Voriconazole is an antifungal agent with in vitro activity and clinical efficacy against yeasts, molds, and dimorphic fungi (eg, Paracoccidioides brasiliensis). The safety profile of voriconazole includes transient visual adverse events (VAEs) that resolve while undergoing treatment or after its discontinuation. OBJECTIVE: The goal of this study was to assess the long-term (ie, 6-12 months) visual safety of voriconazole in adult patients with paracoccidioidomycosis... CONCLUSION: Clinical assessment in this study found no evidence of an effect of voriconazole on long-term visual function in these adult patients with paracoccidioidomycosis. Copyright (c) 2010 Elsevier HS Journals, Inc. Published by EM Inc USA.. All rights reserved.

Single and multidose ocular kinetics and stability analysis of extemporaneous formulation of topical voriconazole in humans. [2010.11]
PURPOSE: The purpose of the present study was to evaluate the kinetics of single and multiple doses of topical, non-preserved voriconazole (VZ) in human eyes... CONCLUSION: The present study showed that the achieved mean concentration of VZ in both single dose and multi dose kinetic studies satisfactorily met the MIC(90) for almost all causative fungal organisms. The frequency of instillation may be designed for an "every 2 hr regimen" to maintain a therapeutic concentration for successful therapy.

more studies >>

Clinical Trials Related to Vfend (Voriconazole)

Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis [Recruiting]
This study compares the effectiveness and safety of the combination of anidulafungin and voriconazole compared to that of voriconazole alone (which is generally considered the standard of care) for the treatment of Invasive Aspergillosis.

Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects [Not yet recruiting]
This study aims to compare the safety, tolerability, and efficacy of voriconazole and anidulafungin in combination versus voriconazole alone in pediatric subjects aged 2 to 17 years with invasive aspergillosis.

Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To Less Than 15 Years Old Who Are At High Risk For Systemic Fungal Infection [Recruiting]
In this study we will measure the concentration of the drug called voriconazole which is used to fight infections caused by fungus in children who usually are cancer patients and have their immune system down. Since we know the dose in adults, and we think we know the matching doses in the young patients ages 2 to less than 15 years old, we will compare the amount of drug that goes into the system with what we know works in adults. We give the drug by a needle directly into the blood, then few days later we stop that and give the drug by mouth. Meanwhile, we draw a little bit of blood at certain times to measure the drug in it.

An Open-Label Study To Assess The Pharmacokinetics, Safety And Toleration Of Vfend®; Following Multiple Dosing With Vfend [Terminated]
This is a study to investigate the pharmacokinetics, safety and tolerability of intravenous voriconazole and SBECD in patients with moderate renal insufficiency

Voriconazole Pharmacokinetics in Children With Gastrointestinal Graft Versus Host Disease [Recruiting]
Determine how much voriconazole is absorbed when the product is given by mouth to children with extensive graft versus host disease after a stem cell transplantation and determine the correct dosing of voriconazole in this population.

Hypothesis: Children with gastrointestinal graft versus host disease will have decreased absorption of oral voriconazole and require higher doses of voriconazole in order to prevent or treat fungal infections.

more trials >>

Reports of Suspected Vfend (Voriconazole) Side Effects

Death (97)Disease Progression (38)Photosensitivity Reaction (37)Pneumonia (23)Visual Impairment (23)Renal Failure (19)Malaise (17)Drug Interaction (16)NO Adverse Event (16)Hepatic Function Abnormal (15)more >>


Page last updated: 2014-09-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014